Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma

Ian L P Beales, Inna Vardi, Leanne Dearman

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Oesophageal adenocarcinoma (OAC) has a poor prognosis, and chemoprevention is an attractive option to reduce the burden of the disease. Hydroxyl-methyl-CoA reductase inhibitors (statins) have been shown to exert potentially useful anticancer effects against OAC cell lines, but there are only limited clinical data examining the effects of statins on the incidence of OAC.
Original languageEnglish
Pages (from-to)917-23
Number of pages7
JournalEuropean Journal of Gastroenterology & Hepatology
Issue number8
Publication statusPublished - Aug 2012


  • Adenocarcinoma
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal
  • Aspirin
  • Barrett Esophagus
  • Case-Control Studies
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Esophageal Neoplasms
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Incidence
  • Male
  • Middle Aged

Cite this